Public alignment with longevity biotechnology: an analysis of framing in surveys and opinion studies.

Abstract

This article examines the framing and public perception of longevity biotechnology, or geroscience, which aims to extend both healthspan and lifespan by targeting the biological processes of aging. Although often seen as moving into the mainstream, questions remain about its ability to meet these ambitious goals, given the complexities of understanding and manipulating aging biology. Drawing on an analysis of qualitative studies and surveys conducted over the past two decades, this paper explores how public attitudes toward anti-aging science are framed, suggesting that studies often emphasize life extension over healthspan gains. Findings reveal mixed reactions, with both interest in and ambivalence about the desirability of extended lifespans. In response, this paper recommends that stakeholders in longevity biotechnology engage with the public by understanding unmet health needs rather than assuming a widespread embrace of lifespan extension. The article underscores the importance of aligning public engagement strategies with realistic scientific expectations to foster credibility and trust; promises should be grounded in current scientific evidence and tempered by feasibility. Addressing societal concerns and fostering dialogue on the ethical and social implications of manipulating aging processes could lay a foundation for responsible progress in geroscience and biogerontology, supporting a more informed, inclusive conversation between science and society as these fields advance.